BioTuesdays

Tag - Maxim Group

Tracon Pharmaceuticals Logo

Maxim starts TRACON Pharma at buy; PT $24

Maxim Group initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $24 price target. The stock closed at $9.91 on Feb. 9. TRACON is developing a differentiated anti-PD-L1 checkpoint...

Cycle-Therapeutics-Logo

Maxim ups Cyclo Therapeutics PT to $25 from $12

Maxim Group more than doubled its price target for Cyclo Therapeutics (NASDAQ:CYTH) to $25 from $12, citing updates from the Phase 1 and Phase 1/2 clinical programs for Trapsol Cyclo (TC) in Neimann-Pick Type C (NPC)...

Lineage-Cell-Therapeutics-Logo

Maxim ups Lineage PT to $5 from $3

Maxim Group raised its price target for Lineage Cell Therapeutics (NYSE American:LCTX) to $5 from $3, citing an agreement with Neurgain Technologies to develop a novel parenchymal delivery injection (PDI) system for...

Cycle-Therapeutics-Logo

Maxim starts Cyclo Therapeutics at buy; PT $12

Maxim Group initiated coverage of Cyclo Therapeutics (NASDAQ:CYTH) with a “buy” rating and $12 price target. The stock closed at $3.85 on Dec. 16. Cyclo is developing a Phase 3-ready hydroxypropyl beta cyclodextrin...

Plus Therapeutics Logo

Maxim starts Plus Therapeutics at buy; PT $6

Maxim Group launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $6. The stock closed at $2.56 on Oct. 15. The company’s lead asset, rhenium nanoliposome (RNL), is being developed...

Onconova Logo

Maxim ups Onconova Therapeutics to buy; PT $1.25

Maxim Group upgraded Onconova Therapeutics (NASDAQ:ONTX) to “buy” from “hold” with a new price target of $1.25, citing a strengthened balance sheet, and a sufficient cash runway into the third quarter of 2021, well past...

Artelo Biosciences Logo

Maxim cuts Artelo Biosciences to hold and removes PT

Maxim Group downgraded Artelo Biosciences (NASDAQ:ARTL) to “hold” from “ buy” without a price target, citing capital concerns. The stock closed at $1.22 on May 12, near the low end of its 52-week range of 61 cents to...

Matinas Biopharma

Maxim cuts Matinas BioPharma PT to $4 from $6

Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.